RxDoctor Payments Data

Shadi Barbu, MD

Neurology · Phoenix, AZNPI 1841678802

Payments from drug & device makers

$7,801in general payments, 2019–2025

Across 155 payments — averaging $50.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$5K
  • Boston Scientific$1K
  • Amneal Pharmaceuticals LLC$447
  • AbbVie$301
  • Revance Therapeutics, Inc.$287
  • Teva Pharmaceuticals USA, Inc.$186
  • plus $741 from 13 others

What the payments were for

  • Travel & lodging$4,28855%
  • Food & beverage$3,51245%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,801 in reported general payments places this provider in the 55th percentile of 388 neurology providers in Arizona.

See all neurology providers in Arizona

Medicare billing

Part B allowed, 2024
$99,875
Medicare patients
280
Services billed
1,085

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate95$544,939
RytaryCarbidopa/Levodopa115$215,605
AustedoDeutetrabenazine12$203,882
IngrezzaValbenazine Tosylate12$103,314
GocovriAmantadine Hcl32$96,972
DuopaCarbidopa/Levodopa15$89,936
Austedo XrDeutetrabenazine13$67,553
InbrijaLevodopa12$66,138
Carbidopa-LevodopaCarbidopa/Levodopa889$28,188
Carbidopa-Levodopa ErCarbidopa/Levodopa300$20,706
NeuproRotigotine11$19,183
Rasagiline Mesylate38$11,222
AmantadineAmantadine Hcl184$9,424
LinzessLinaclotide12$6,404
Entacapone26$5,021

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$141$544,93995 claims
Teva Pharmaceuticals USA, Inc.Austedo, Austedo Xr$186$271,43525 claims
Amneal Pharmaceuticals LLCRytary$447$215,605115 claims
Neurocrine Biosciences, Inc.Ingrezza$84$103,31412 claims
MDD US Operations, LLCGocovri$86$96,97232 claims
AbbVieDuopa, Linzess$301$96,34027 claims
Acorda Therapeutics, IncInbrija$39$66,13812 claims
UCB, Inc.Neupro$15$19,18311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 388 neurology providers in Arizona.

Other neurology in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →